hydroxychloroquine plus macrolides in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Sbidian (HCQ plus AZI), 2020 1.40 [1.03; 1.90]
1.40 [1.03 ; 1.90 ] Sbidian (HCQ plus AZI), 2020 1 0% 4,019 NA not evaluable death or transfer to ICUdetailed results Davido, 2020 0.45 [0.21; 0.97]
0.45 [0.21 ; 0.97 ] Davido, 2020 1 0% NA not evaluable deathsdetailed results Arshad (HCQ AZ), 2020 0.29 [0.22; 0.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Duke university HCQ-AZI, 2020 3.00 [0.04; 207.00]
Ip, 2020 0.98 [0.75; 1.28]
Lagier, 2020 0.49 [0.25; 0.97]
Magagnoli (HC AZ), 2020 1.14 [0.56; 2.32]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
Rosenberg, 2020 1.35 [0.76; 2.40]
Sbidian (HCQ plus AZI), 2020 1.40 [1.03; 1.90]
Singh, 2020 1.19 [0.89; 1.60]
0.84 [0.53 ; 1.33 ] Arshad (HCQ AZ), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Duke university HCQ-AZI, 2020, Ip, 2020, Lagier, 2020, Magagnoli (HC AZ), 2020, ProPAC-COVID, 2021, Rosenberg, 2020, Sbidian (HCQ plus AZI), 2020, Singh, 2020 10 88% 11,046 serious low deaths (time to event analysis only)detailed results Arshad (HCQ AZ), 2020 0.29 [0.22; 0.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Magagnoli (HC AZ), 2020 1.14 [0.56; 2.32]
Rosenberg, 2020 1.35 [0.76; 2.40]
Sbidian (HCQ plus AZI), 2020 1.40 [1.03; 1.90]
0.84 [0.37 ; 1.92 ] Arshad (HCQ AZ), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Magagnoli (HC AZ), 2020, Rosenberg, 2020, Sbidian (HCQ plus AZI), 2020 5 93% 6,907 serious not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Lagier, 2020 0.30 [0.22; 0.41]
0.53 [0.17 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Lagier, 2020 2 92% 4,181 serious not evaluable clinical improvementdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
0.81 [0.54 ; 1.22 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 444 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
1.01 [0.58 ; 1.76 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 444 NA not evaluable clinical improvement (7-day)detailed results Tsiakos, 2020 2.36 [1.10; 5.09]
2.36 [1.10 ; 5.09 ] Tsiakos, 2020 1 0% 180 NA not evaluable hospitalizationdetailed results Lagier, 2020 0.38 [0.27; 0.54]
0.38 [0.27 ; 0.54 ] Lagier, 2020 1 0% 3,737 NA not evaluable mechanical ventilationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
Singh, 2020 0.98 [0.64; 1.49]
1.20 [0.69 ; 2.08 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Singh, 2020 2 42% 1,747 serious not evaluable mechanical ventilation (time to event analysis only)detailed results Magagnoli (HC AZ), 2020 0.43 [0.16; 1.14]
0.43 [0.16 ; 1.14 ] Magagnoli (HC AZ), 2020 1 0% NA not evaluable ICU admissiondetailed results ProPAC-COVID, 2021 1.24 [0.26; 5.80]
1.24 [0.26 ; 5.80 ] ProPAC-COVID, 2021 1 0% 117 NA not evaluable cardiac arrestdetailed results Rosenberg, 2020 2.13 [1.12; 4.05]
2.13 [1.12 ; 4.05 ] Rosenberg, 2020 1 0% NA not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
1.87 [0.36 ; 9.75 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable abnormal ECG findingsdetailed results Rosenberg, 2020 1.55 [0.89; 2.68]
1.55 [0.89 ; 2.68 ] Rosenberg, 2020 1 0% NA not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
2.22 [1.43 ; 3.44 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
Rosenberg, 2020 2.21 [1.38; 3.52]
2.21 [1.40 ; 3.49 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Rosenberg, 2020 2 0% 1,372 serious not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 174 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-23 11:21 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 559,889
- roots T: 290
